Lynn M. Rundhaugen

Structure-function relationships of the dietary anticarcinogen ellagic acid

Lynn M. Rundhaugen, Gary D. Stoner, N.Sokalingum Pillay et al. · Carcinogenesis · 1996 · 80 citations

Medicine, Biochemistry, Pharmacology +17

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

Chadi Nabhan, Lynn M. Rundhaugen, Mary Beth Riley et al. · Leukemia Research · 2004 · 75 citations

Medicine, Hematology, Oncology +12

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Simrit Parmar, Lynn M. Rundhaugen, Larry Boehlke et al. · Leukemia Research · 2004 · 57 citations

Medicine, Hematology, Oncology +16

Ellagic acid induces transcription of the rat glutathione S-transferase-Ya gene

David H. Barch, Lynn M. Rundhaugen, N.Sokalingum Pillay · Carcinogenesis · 1995 · 43 citations

Life Sciences, Molecular Biology, Oncology +7

Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene

David H. Barch, Lynn M. Rundhaugen · Carcinogenesis · 1994 · 32 citations

Life Sciences, Biochemistry, Oncology +13